Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

BACKGROUND: Cediranib, an oral anti-angiogenic VEGFR 1-3 inhibitor, was studied at a daily dose of 20 mg in combination with platinum-based chemotherapy and as maintenance in a randomised trial in patients with first relapse of ‘platinum-sensitive’ ovarian cancer and has been shown to improve progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Ledermann, J.A., Embleton-Thirsk, A.C., Perren, T.J., Jayson, G.C., Rustin, G.J.S., Kaye, S.B., Hirte, H., Oza, A., Vaughan, M., Friedlander, M., González-Martín, A., Deane, E., Popoola, B., Farrelly, L., Swart, A.M., Kaplan, R.S., Parmar, M.K.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903311/
https://www.ncbi.nlm.nih.gov/pubmed/33610123
http://dx.doi.org/10.1016/j.esmoop.2020.100043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903311/
https://www.ncbi.nlm.nih.gov/pubmed/33610123
http://dx.doi.org/10.1016/j.esmoop.2020.100043

Ejemplares similares